Going Once, Going Twice, Sold! Cinven and Bain Capital to Acquire STADA for €5.3bn after Intense Bidding War

Stada Arzneimittel AG (FWB: SAZ) – market cap as of 21/04/2017: €4.02bn Intel Cinven Partners LLP – private company – AUM as of FY 2015: €10.60bn Bain Capital Private Equity, LP – private company – AUM as of 04/04/2017: $32.40bn Introduction On April 10, 2017, Bain Capital Private Equity, LP Read more…

Go big or go home – Reckitt Benckiser to acquire Mead Johnson for $17.9bn

Reckitt Benckiser Group (LON: RB) – market cap as of 17/02/2017: $61.7bn (£49.71bn) Mead Johnson Nutrition Company (NYSE: MJN) – market cap as of 17/02/2017: $16.05bn Introduction On 10 February 2017, UK-based consumer goods multinational Reckitt Benckiser (RB) and US-based infant nutrition leader Mead Johnson reached an agreement by means Read more…

Tireless Shire: Another Deal in Pharma M&A Wave

Shire PLC; market cap: $28.38bn (as of 06/11/2015) Dyax Corporation; market cap: $5.1bn (as of 06/11/2015)   Introduction On November 2, Dublin-headquartered pharmaceutical company Shire Plc agreed to acquire the Massachusetts-based biopharma company Dyax Corporation for an upfront cash consideration of $5.9bn and an additional $646m payment contingent on the Read more…

Teva Pharmaceuticals Heading to the Emerging Markets

Teva Pharmaceuticals Industries Ltd. (TEVA); market cap (as of 02/10/2015): $51.05bn.   Introduction Following a wave of consolidation in the healthcare industry, Teva Pharmaceuticals Industries Ltd. and Representaciones e Investigaciones Médicas, S.A. de C.V. (Rimsa) announced on October 1 that they have entered into a definitive agreement under which Teva Read more…

Pfizer sets sail for a new (nearer) shore: Hospira

Pfizer Inc.; market cap (as of 20/02/2015): US$217.75bn Hospira Inc.; market cap (as of 20/02/2015): US$14.97bn Introduction On February 5th, 2014, pharmaceutical behemoth Pfizer signed with Hospira, the world’s leading provider of injectable drugs and biosimilars, a definitive merger agreement which consists of the fully acquisition of Hospira for US$90 Read more…

Get a $66bn Smile: Actavis to buy the Botox-maker Allergan

Actavis plc.; market cap (as of 21/11/2014): $70.5bn Allergan Inc.; market cap (as of 21/11/2014): $63.3bn Introduction The growing emphasis we put on health and quality of life, and the scientific advancements which are making this possible, are putting the pharmaceutical and medical industries in the spotlight. The recent surge Read more…